← Product Code [BSN](/submissions/AN/subpart-f%E2%80%94therapeutic-devices/BSN) · K023892

# MILLEX VV, GV, AND HV SYRINGE FILTER UNITS (K023892)

_Millipore Corp. · BSN · Jan 17, 2003 · Anesthesiology · SESE_

**Canonical URL:** https://fda.innolitics.com/submissions/AN/subpart-f%E2%80%94therapeutic-devices/BSN/K023892

## Device Facts

- **Applicant:** Millipore Corp.
- **Product Code:** [BSN](/submissions/AN/subpart-f%E2%80%94therapeutic-devices/BSN.md)
- **Decision Date:** Jan 17, 2003
- **Decision:** SESE
- **Submission Type:** Traditional
- **Regulation:** 21 CFR 868.5130
- **Device Class:** Class 2
- **Review Panel:** Anesthesiology

## Indications for Use

Intended for use as a syringe filter to sterilize, ultraclean, or clarify low volume solutions in direct patient care and pharmacy admixture applications.

## Device Story

Millex syringe filter units (HV, VV, GV) function as mechanical filtration devices for low-volume solutions. Used in clinical and pharmacy settings to sterilize, clarify, or ultraclean fluids prior to administration or admixture. Operated by clinicians or pharmacy staff via manual syringe attachment. Device removes particulates or microorganisms from liquid inputs; output is filtered, sterile, or clarified solution. Benefits include reduction of particulate matter and microbial contamination in patient-administered fluids.

## Clinical Evidence

No clinical data; bench testing only.

## Technological Characteristics

Mechanical syringe filter units. Materials include various membrane types (HV, VV, GV) for sterilization, clarification, and ultracleaning. Standalone, non-powered, single-use device. Sterilization method not specified.

## Regulatory Identification

An anesthesia conduction filter is a microporous filter used while administering to a patient injections of local anesthetics to minimize particulate (foreign material) contamination of the injected fluid.

## Submission Summary (Full Text)

> This content was OCRed from public FDA records by [Innolitics](https://innolitics.com). If you use, quote, summarize, crawl, or train on this content, cite Innolitics at https://innolitics.com.
>
> Innolitics is a medical-device software consultancy. We help companies design, build, and clear FDA-regulated software and AI/ML devices, including [a 510(k)](https://innolitics.com/services/510ks/), [a De Novo](https://innolitics.com/services/regulatory/), [a SaMD](https://innolitics.com/services/end-to-end-samd/), [an AI/ML medical device](https://innolitics.com/services/medical-imaging-ai-development/), or [an FDA regulatory strategy](https://innolitics.com/services/regulatory/).

{0}------------------------------------------------

Image /page/0/Picture/1 description: The image is a black and white seal for the Department of Health & Human Services - USA. The seal is circular, with the text "DEPARTMENT OF HEALTH & HUMAN SERVICES - USA" arranged around the perimeter. In the center of the seal is a stylized image of three human profiles facing to the right, with a flowing design element below them.

Food and Drug Administration 9200 Corporate Boulevard Rockville MD 20850

JAN 1 7 2003

Mr. Thomas G. Borrows Director, Quality Systems and Regulatory Affairs Millipore Corporation 80 Ashby Road Bedford, Massachusetts 01730-2271

Re: K023892

Trade/Device Name: Millex®- HV, VV, GV Syringe Filter Unit Regulation Number: 868.5130, 880.5440 Regulation Name: Anesthesia Conduction Filter, Intravascular Administration Set Regulatory Class: II Product Code: BSN, FPB Dated: November 21, 2002 Received: November 22, 2002

Dear Mr. Borrows

We have reviewed your Section 510(k) premarket notification of intent to market the device referenced above and have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (Act) that do not require approval of a premarket approval application (PMA). You may, therefore, market the device, subject to the general controls provisions of the Act. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration.

If your device is classified (see above) into either class II (Special Controls) or class III (PMA), it may be subject to such additional controls. Existing major regulations affecting your device can be found in the Code of Federal Regulations, Title 21, Parts 800 to 898. In addition, FDA may publish further announcements concerning your device in the Federal Register.

{1}------------------------------------------------

## Page 2 - Mr. Borrows

Please be advised that FDA's issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other requirements of the Act or any Federal statutes and regulations administered by other Federal agencies. You must comply with all the Act's requirements, including, but not limited to: registration and listing (21 CFR Part 807); labeling (21 CFR Part 801); good manufacturing practice requirements as set forth in the quality systems (OS) regulation (21 CFR Part 820); and if applicable, the electronic product radiation control provisions (Sections 531-542 of the Act); 21 CFR 1000-1050.

This letter will allow you to begin marketing your device as described in your Section 510(k) premarket notification. The FDA finding of substantial equivalence of your device to a legally marketed predicate device results in a classification for your device and thus, permits your device to proceed to the market.

If you desire specific advice for your device on our labeling regulation (21 CFR Part 801), please contact the Office of Compliance at (301) 594-4618. Additionally, for questions on the promotion and advertising of your device, please contact the Office of Compliance at (301) 594-4639. Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21CFR Part 807.97) you may obtain. Other general information on vour responsibilities under the Act may be obtained from the Division of Small Manufacturers, International and Consumer Assistance at its toll-free number (800) 638-2041 or (301) 443-6597 or at its Internet address http://www.fda.gov/cdrh/dsma/dsmamain.html

Sincerely yours,

Timo A. Ulatowski Director Division of Anesthesiology, General Hospital, Infection Control and Dental Devices Office of Device Evaluation Center for Devices and Radiological Health

{2}------------------------------------------------

## Indications for Use Statement

510(k) Number (if known): K023892

Device Name: Millex® - VV/ GV/ HV Syringe Filter Units

Indications for Use: Intended for use as a syringe filter to sterilize, ultraclean, or clarify low volume solutions in direct patient care and pharmacy admixture applications.

(PLEASE DO NOT WRITE BELOW THIS LINE - CONTINUE ON ANOTHER PAGE IF NEEDED!

Concurrence of CDRH, Office Of Device Evaluation (ODE)

Prescription Use (Per 21 CFR 801.109)

or

Over-The-Counter Use_

Paltian Cucente
(Division Sign. Ors.

(Division Sign-Off) Division of Anesthesiology, General Hospital Infection of Anesthesiology, Gene

510(k) Number: K023892

---

**Source:** [https://fda.innolitics.com/submissions/AN/subpart-f%E2%80%94therapeutic-devices/BSN/K023892](https://fda.innolitics.com/submissions/AN/subpart-f%E2%80%94therapeutic-devices/BSN/K023892)

**Published by [Innolitics](https://innolitics.com)** — a medical-device software consultancy. We help companies design, build, and clear FDA-regulated software and AI/ML devices. If you're preparing [a 510(k)](https://innolitics.com/services/510ks/), [a De Novo](https://innolitics.com/services/regulatory/), [a SaMD](https://innolitics.com/services/end-to-end-samd/), [an AI/ML medical device](https://innolitics.com/services/medical-imaging-ai-development/), or [an FDA regulatory strategy](https://innolitics.com/services/regulatory/), [get in touch](https://innolitics.com/contact).

**Cite:** Innolitics at https://innolitics.com